5 results
To evaluate in detail the functionality of immune cells in blood in chronic HCV patients before, during and after treatment with ASV and DCV, in an IFN-free regimen.
Efficacy and safety during 24 treatment weeks.
Primary: To demonstrate non-inferiority of RELVAR 100/25 once-daily to SERETIDE 250/50 twice-daily in adult and adolescent subjects 12 years of age and older with persistent asthma,adequately controlled on twice-daily ICS/LABA. Secondary: Adverse…
Primary objective:- To determine the safety and optimal dose of three doses of a novel therapeutic vaccine (ISA104) consisting of 12 synthetic long peptides, as well as an adjuvant agent (AmplivantTM), in patients with chronic hepatitis B (cHBV),…
To determine the safety and effectiveness of a vFFR guided strategy versus an invasive FFR guided strategy for coronary revascularization.